Follow-up or surveillance 18F-FDG PET/CT and survival outcome in lung cancer patients

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1062-1068

  Antoniou, Alexander J ^a   Marcus, Charles ^a   Tahari, Abdel K ^a   Wahl, Richard L ^a   Subramaniam, Rathan M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Lung cancer; PET; Surveillance; Survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING HABIT; SURVIVAL TIME; WHOLE BODY SCINTISCANNING; LUNG NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; SCINTISCANNING;

AGE FACTORS; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904115991     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.136770     Document Type: Article

References (25)

1. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi89-vi98.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975-2010. National Cancer Institute website. http://seer.cancer.gov/csr/ 1975-2010/. Based on November 2012 SEER data submission. Posted to the SEER website April 2013. Updated June 14, 2013. Accessed April 14, 2014.
3. Colice GL, Rubins J, Unger M, et al. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest. 2003;123(suppl):272S-283S. (Pubitemid 36135722)
4. Lou F, Huang J, Sima CS, et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013;145:75-81.
5. Dane B, Grechushkin V, Plank A, et al. PET/CT vs. non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer. Am J Nucl Med Mol Imaging. 2013;3:408-416.
6. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J. 1999;14:1376-1380. (Pubitemid 30019536)
7. Choi SH, Kim YT, Kim SK, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92:1826-1832.
8. He YQ, Gong HL, Deng YF, et al. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol. 2014;55:309-317.
9. Kanzaki R, Higashiyama M, Maeda J, et al. Clinical value of F18-fluorodeoxy-glucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg. 2010;10:1009-1014.
10. Opoka L, Szołkowska M, Podgajny Z, et al. Assessment of recurrence of non-small cell lung cancer after therapy using CT and integrated PET/CT. Pneumonol Alergol Pol. 2013;81:214-220.
11. Saunders CA, Dussek JE, O'Doherty MJ, et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790-797. (Pubitemid 29207699)
12. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507. (Pubitemid 36706537)
13. Hellwig D, Gröschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:13-21. (Pubitemid 41785304)
14. Fischer BM, Mortensen J. The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration. 2006;73:267-276. (Pubitemid 43725781)
15. Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
16. 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med. 2013;54:2039-2045.
17. Agarwal A, Chirindel A, Shah BA, Subramaniam RM. Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR. 2013;200:884-890.
18. Birth, marriage, and death search page. Ancestry.com website. http://search.ancestry.com/search/category.aspx?cat534. Accessed April 14, 2014.
19. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001;42:1605-1613.
20. Gregory DL, Hicks RJ, Hogg A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53:1007-1015.
21. 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004;45:1640-1646.
22. Seltzer MA, Yap CS, Silverman DH, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med. 2002;43:752-756. (Pubitemid 34663295)
23. 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts. J Nucl Med. 2012;53:831-837.
24. Cho S, Lee EB. A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg. 2010;139:1447-1451.
25. van Rens MT, de la Rivière AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest. 2000;117:374-379. (Pubitemid 30111585)